title: Cerebral oxygenation during prostaglandin E1 induced hypotension.
abstract: OBJECTIVE
  To evaluate the cerebral oxygenation effects of hypotension induced by prostaglandin E1 (PGE1) during fentanyl-oxygen anaesthesia.
  
  
  METHODS
  Ten patients who underwent elective cardiac surgery received infusion of PGE1. After measuring the baseline arterial, mixed venous and internal jugular vein blood gases, systemic haemodynamics, and regional cerebral oxygen saturation (rSO2) estimated by INVOS 3100R, PGE1 was continuously infused at 0.25-0.65 microgram.kg-1.min-1 (mean dosage: 410 +/- 41.4 mg.kg-1.min-1) intravenously. Ten, 20 and 30 minutes after the start of drug infusions, blood gases described above were obtained simultaneously with the measurement of systemic haemodynamics and rSO2. Thirty minutes from the start of drug infusions, administration of PGE1 was stopped. The same parameters were measured again 10, 30 minutes after the stop of drug infusion.
  
  
  RESULTS
  PGE1 decreased mean arterial pressure (MAP) to approximately 70% of the baseline value (P < 0.05). PGE1 increased mixed venous saturation, but in contrast did not affect internal jugular pressure, internal jugular oxygen saturation and rSO2.
  
  
  CONCLUSIONS
  These results suggest that PGE1 is a suitable drug for induced hypotension because flow/metabolism coupling of brain and regional cerebral oxygenation were well maintained during hypotension.
authors.affiliation: Department of Anaesthesiology and Reanimatology, Gunma University, School of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Kadoi
authors.forename: S
authors.initials: S
authors.lastname: Saito
authors.forename: F
authors.initials: F
authors.lastname: Kunimoto
authors.forename: T
authors.initials: T
authors.lastname: Morita
authors.forename: F
authors.initials: F
authors.lastname: Goto
authors.forename: F
authors.initials: F
authors.lastname: Kawahara
authors.forename: N
authors.initials: N
authors.lastname: Fujita
mesh_terms: D000527:Alprostadil / Q000008:administration & dosage / Q000627:therapeutic use*; D000771:Anesthesia, Intravenous; D018686:Anesthetics, Intravenous / Q000008:administration & dosage; D001794:Blood Pressure / Q000187:drug effects; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D002245:Carbon Dioxide / Q000097:blood; D002302:Cardiac Output / Q000187:drug effects; D002496:Central Venous Pressure / Q000187:drug effects; D002560:Cerebrovascular Circulation / Q000187:drug effects; D001026:Coronary Artery Bypass; D017558:Elective Surgical Procedures; D005283:Fentanyl / Q000008:administration & dosage; D006339:Heart Rate / Q000187:drug effects; D019918:Heart Valve Prosthesis Implantation; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007023:Hypotension, Controlled / Q000379:methods; D007262:Infusions, Intravenous; D008875:Middle Aged; D010100:Oxygen / Q000008:administration & dosage / Q000097:blood; D010101:Oxygen Consumption / Q000187:drug effects*; D010313:Partial Pressure; D019265:Spectroscopy, Near-Infrared; D013997:Time Factors; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D018686:Anesthetics, Intravenous; D014665:Vasodilator Agents; D002245:Carbon Dioxide; D000527:Alprostadil; D010100:Oxygen; D005283:Fentanyl